直接口服抗凝药与低分子肝素在癌症患者复发性静脉血栓栓塞中的比较:一项随机临床试验
这项在美國67家肿瘤诊疗机构开展的非盲、实效性、非劣效随机临床试验纳入671例新诊断静脉血栓栓塞的癌症患者,随机接受直接口服抗凝药或低分子肝素治疗并随访6个月。直接口服抗凝药组6个月复发性静脉血栓栓塞发生率为6.1%,低分子肝素组为8.8%,差异-2.7%(单侧95%CI,-100%至0.7%),符合预设非劣效标准;大出血发生率两组分别为5.2%和5.6%,差异-0.4%(单侧95%CI,-100%至2.5%),未达到非劣效标准。
要点
- 在癌症合并静脉血栓栓塞患者中,直接口服抗凝药预防6个月复发性静脉血栓栓塞非劣效于低分子肝素。
- 直接口服抗凝药组复发性静脉血栓栓塞6.1%,低分子肝素组8.8%,差异-2.7%(单侧95%CI,-100%至0.7%)。
- 大出血直接口服抗凝药组5.2% vs 低分子肝素组5.6%,差异-0.4%(单侧95%CI,-100%至2.5%),未达非劣效标准。
核心结论
- 在癌症合并静脉血栓栓塞的成人患者中,直接口服抗凝药预防6个月复发性静脉血栓栓塞非劣效于低分子肝素。
- 这些发现支持在癌症患者中使用直接口服抗凝药预防复发性静脉血栓栓塞。
研究设计与样本
- 非盲、实效性、非劣效随机临床试验,在美国67家肿瘤诊疗机构开展。
- 纳入671例新发临床或影像学诊断静脉血栓栓塞的癌症患者(任何侵袭性实体瘤、淋巴瘤、多发性骨髓瘤或慢性淋巴细胞白血病)。
- 入组时间为2016年12月至2020年4月,最终随访时间为2020年11月。
- 参与者按1:1随机分配至直接口服抗凝药组(n=335)或低分子肝素组(n=336),随访6个月或直至死亡。
- 医生和患者选择任何直接口服抗凝药或任何低分子肝素(或磺达肝癸钠),医生选择药物剂量。
主要发现
- 直接口服抗凝药组6个月复发性静脉血栓栓塞发生率为6.1%,低分子肝素组为8.8%,差异-2.7%(单侧95%CI,-100%至0.7%),符合预设非劣效标准。
- 6个预设次要结局均无统计学显著性。
- 大出血在直接口服抗凝药组发生率为5.2%,低分子肝素组为5.6%,差异-0.4%(单侧95%CI,-100%至2.5%),未达到非劣效标准。
- 严重不良事件在直接口服抗凝药组发生率为33.8%,低分子肝素组为35.1%。
- 最常见的严重不良事件为贫血和死亡。
关键数值与推荐
- 主要结局为6个月复发性静脉血栓栓塞率,非劣效定义为直接口服抗凝药相对低分子肝素差异的单侧95%CI上限小于3%。
- 大出血采用2.5%非劣效界值评估。
临床怎么用
- 原文结论指出这些发现支持在癌症患者中使用直接口服抗凝药预防复发性静脉血栓栓塞。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In patients with cancer who have venous thromboembolism (VTE) events, long-term anticoagulation with low-molecular-weight heparin (LMWH) is recommended to prevent recurrent VTE. The effectiveness of a direct oral anticoagulant (DOAC) compared with LMWH for preventing recurrent VTE in patients with cancer is uncertain. OBJECTIVE: To evaluate DOACs, compared with LMWH, for preventing recurrent VTE and for rates of bleeding in patients with cancer following an initial VTE event. DESIGN, SETTING, AND PARTICIPANTS: Unblinded, comparative effectiveness, noninferiority randomized clinical trial conducted at 67 oncology practices in the US that enrolled 671 patients with cancer (any invasive solid tumor, lymphoma, multiple myeloma, or chronic lymphocytic leukemia) who had a new clinical or radiological diagnosis of VTE. Enrollment occurred from December 2016 to April 2020. Final follow-up was in November 2020. INTERVENTION: Participants were randomized in a 1:1 ratio to either a DOAC (n = 335) or LMWH (n = 336) and were followed up for 6 months or until death. Physicians and patients selected any DOAC or any LMWH (or fondaparinux) and physicians selected drug doses. MAIN OUTCOMES AND MEASURES: The primary outcome was the recurrent VTE rate at 6 months. Noninferiority of anticoagulation with a DOAC vs LMWH was defined by the upper limit of the 1-sided 95% CI for the difference of a DOAC relative to LMWH of less than 3% in the randomized cohort that received at least 1 dose of assigned treatment. The 6 prespecified secondary outcomes included major bleeding, which was assessed using a 2.5% noninferiority margin. RESULTS: Between December 2016 and April 2020, 671 participants were randomized and 638 (95%) completed the trial (median age, 64 years; 353 women [55%]). Among those randomized to a DOAC, 330 received at least 1 dose. Among those randomized to LMWH, 308 received at least 1 dose. Rates of recurrent VTE were 6.1% in the DOAC group and 8.8% in the LMWH group (difference, -2.7%; 1-sided 95% CI, -100% to 0.7%) consistent with the prespecified noninferiority criterion. Of 6 prespecified secondary outcomes, none were statistically significant. Major bleeding occurred in 5.2% of participants in the DOAC group and 5.6% in the LMWH group (difference, -0.4%; 1-sided 95% CI, -100% to 2.5%) and did not meet the noninferiority criterion. Severe adverse events occurred in 33.8% of participants in the DOAC group and 35.1% in the LMWH group. The most common serious adverse events were anemia and death. CONCLUSIONS AND RELEVANCE: Among adults with cancer and VTE, DOACs were noninferior to LMWH for preventing recurrent VTE over 6-month follow-up. These findings support use of a DOAC to prevent recurrent VTE in patients with cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02744092.
引用
- Schrag D, Uno H, Rosovsky R, et al. Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial. JAMA. 2023. PMID: 37266947. doi:10.1001/jama.2023.7843
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。